Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.27 EUR | -2.00% | +6.48% | -51.74% |
May. 14 | Centogene, Evotec Discover New Molecule for Potential Gaucher Disease Treatment | MT |
May. 14 | Centogene N.V and Evotec SE Discovers Promising New Molecule to Treat Gaucher Disease | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-51.74% | 2.02B | A- | ||
+33.37% | 49.46B | B- | ||
+1.55% | 42.58B | B | ||
+49.11% | 42.49B | A | ||
-4.22% | 29.09B | C | ||
+11.57% | 26.61B | B- | ||
-21.00% | 18.64B | B | ||
+7.36% | 13.16B | B+ | ||
+28.30% | 12.55B | C+ | ||
+23.80% | 12.1B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EVT Stock
- Ratings Evotec SE